Physician profile
David W Murphy
NPI 1639280647
$2,625.12
in general payments reported to CMS, 2019-2025
28 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $237 · 2021: $478 · 2022: $181 · 2023: $128 · 2024: $256 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $380.33 | 2019-2025 | Repatha, Otezla |
| Pfizer INC. | $280.01 | 2019-2025 | |
| Novo Nordisk INC | $268.50 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $261.44 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $249.27 | 2019-2025 | |
| Amarin Pharma, INC. | $175.39 | 2019-2020 | |
| Lilly USA, LLC | $148.33 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $145.50 | 2019-2022 | |
| Antares Pharma, INC. | $76.28 | 2019-2020 | |
| Glaxosmithkline, LLC. | $70.00 | 2019-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.57 | 2021 | |
| Sanofi-Aventis U.S. LLC | $54.21 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $50.97 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $49.66 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $48.87 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.27 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $41.38 | 2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $33.61 | 2019-2020 | |
| Boston Scientific Corporation | $31.73 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $30.60 | 2021 | |
| Phathom Pharmaceuticals, INC. | $23.97 | 2025 | Voquezna |
| Esperion Therapeutics, INC. | $18.45 | 2025 | Nexletol |
| Allergan, INC. | $16.42 | 2020 | |
| Mannkind Corporation | $16.29 | 2020 | |
| Exact Sciences Corporation | $15.01 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $13.48 | 2021 | |
| Abbott Laboratories | $12.56 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.